Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00567060
Other study ID # N01001
Secondary ID
Status Completed
Phase N/A
First received November 30, 2007
Last updated December 13, 2013
Start date May 2000
Est. completion date January 2004

Study information

Verified date September 2009
Source UCB Pharma
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

The purpose of this study was to explore in a more documented way the relative potential and efficacy of piracetam 9600 and 4800 mg daily.


Recruitment information / eligibility

Status Completed
Enrollment 676
Est. completion date January 2004
Est. primary completion date January 2004
Accepts healthy volunteers No
Gender Both
Age group 50 Years to 89 Years
Eligibility Inclusion Criteria:

- male/female between 50 and 89 years (inclusive)

- declining cognitive function of at least 3 months duration interfering with complex activities of daily living

- normal basic activities of daily independent living

- Clinical Dementia Rating scale score equal to 0.5

- score at least one point above the lowest possible score on 7 out of 8 tests in the cognitive battery at both Selection Visit and Baseline Visit

Exclusion Criteria:

- general anesthetics within 3 months of selection visit

- history of severe allergic drug reaction(s)

- history of drug or alcohol dependence (DSM IV defined) within the last 12 months

- any drug prescribed to activate cerebral metabolism, taken within 1 week of screening or/and concomitantly

- concomitant intake of anticoagulent medications

- concomitant intake or intake within 1 week before screening of drug that might affect cognitive function or central nervous system

- history of dementia, psychiatric or neurological disorders, mental retardation, learning disabilities and stroke

- current depression

- impaired renal function, thyroid function or neurological degeneration

- any gastrointestinal dysfunction that might interfere with the absorption or elimination of the study drug

- insulin-dependant diabetes mellitus

- bleeding disorders or disturbance in hemostatic function.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Piracetam


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
UCB Pharma

References & Publications (1)

Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):429-38. Epub 2005 Nov 23. Review. Erratum in: J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):892. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cognitive Battery Composite Score over a 52-week period
Secondary safety of piracetam for 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03894254 - Predictive Factors of Autonomy Loss in Real-life Cohort N/A
Not yet recruiting NCT03507985 - Attention and Memory Disorders Related to Acute Morphine
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT00355498 - Amyloid Plaque and Tangle Imaging in Aging and Dementia
Completed NCT00010920 - Preventing Cognitive Decline With Alternative Therapies Phase 3
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Completed NCT02185222 - Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint Phase 3
Completed NCT00289471 - Identifying Patients With Dementia in Primary Care N/A
Terminated NCT00548327 - The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Phase 2
Completed NCT00403507 - Exercise Treatment of Mild-Stage Probable Alzheimer's Disease Phase 2
Completed NCT00387062 - Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment Phase 1
Completed NCT04587583 - WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers Phase 1/Phase 2
Completed NCT02843529 - Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI) N/A
Active, not recruiting NCT03205709 - Cognitive Training and Neuroplasticity in Mild Cognitive Impairment N/A
Recruiting NCT05509075 - Nutraceuticals and Functional Foods
Recruiting NCT05065450 - Amygdala Memory Enhancement N/A
Recruiting NCT05929144 - Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases N/A
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Completed NCT02333942 - Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
Completed NCT02236416 - Physical Exercise for Prevention of Dementia N/A